prevotellacombri是prevotella属在肠道中的优势种,这是基因组异质性的,很难分离;因此,对这个物种进行了很少的研究。本研究旨在探讨P.copri对高血糖的影响。从健康个体中分离出39株,选择葡萄糖消耗最高的三种菌株(HF2123,HF1478和HF2130)来评估补充P.copri对高血糖的影响。微生物和非靶代谢组学被用来揭示潜在的机制。在糖尿病db/db小鼠中口服P.copri可增加胰高血糖素样肽-1(GLP-1)的表达和分泌,显著改善高血糖,胰岛素抵抗,和脂质积累,减轻了胰腺的病理形态,肝脏,和结肠。P.copri改变了糖尿病db/db小鼠的肠道菌群组成,其特点是增加拟杆菌与厚壁菌的比例,增加拟杆菌属的相对丰度,Akkermansia,和粪杆菌.在接受P.copri干预后,粪便代谢谱显示富马酸和同型半胱氨酸含量降低,谷氨酰胺含量增加。此外,氨基酸代谢和cAMP/PKA信号通路的富集。我们的发现表明P.copri改善了糖尿病db/db小鼠的葡萄糖代谢异常。尤其是,其中一种P.copri菌株,HF2130在改善高血糖方面表现出卓越的性能,它可能具有作为抗高血糖的益生菌的潜力。
目的:作为人类肠道生态系统的核心成员,在先前的研究中,precvotelalcopri与葡萄糖代谢稳态有关。然而,这些结果通常来自宏基因组研究,并且实验研究仅基于菌株DSM18205T的类型。因此,根据其高度的基因组异质性,需要更多来自其他分离株的实验证据来验证结果.在这项研究中,我们分离了不同分支的菌株,并证明了P.copri可以通过调节微生物活性来改善高血糖小鼠的代谢谱。这一发现支持了P.copri在宿主葡萄糖代谢中的因果贡献。
Prevotella copri is the dominant species of the Prevotella genus in the gut, which is genomically heterogeneous and difficult to isolate; hence, scarce research was carried out for this species. This study aimed to investigate the effect of P. copri on
hyperglycemia. Thirty-nine strains were isolated from healthy individuals, and three strains (HF2123, HF1478, and HF2130) that had the highest glucose consumption were selected to evaluate the effects of P. copri supplementation on
hyperglycemia. Microbiomics and non-target metabolomics were used to uncover the underlying mechanisms. Oral administration of P. copri in diabetic db/db mice increased the expression and secretion of glucagon-like peptide-1 (GLP-1), significantly improved
hyperglycemia, insulin resistance, and lipid accumulation, and alleviated the pathological morphology in the pancreas, liver, and colon. P. copri changed the composition of the gut microbiota of diabetic db/db mice, which was characterized by increasing the ratio of Bacteroidetes to Firmicutes and increasing the relative abundance of genera Bacteroides, Akkermansia, and Faecalibacterium. After intervention with P. copri, fecal metabolic profiling showed that fumaric acid and homocysteine contents decreased, and glutamine contents increased. Furthermore, amino acid metabolism and cAMP/PKA signaling pathways were enriched. Our findings indicate that P. copri improved glucose metabolism abnormalities in diabetic db/db mice. Especially, one of the P. copri strains, HF2130, has shown superior performance in improving
hyperglycemia, which may have the potential as a probiotic against
hyperglycemia.
OBJECTIVE: As a core member of the human intestinal ecosystem, Prevotelal copri has been associated with glucose metabolic homeostasis in previous studies. However, these results have often been derived from metagenomic studies, and the experimental studies have been based solely on the type of strain DSM 18205T. Therefore, more experimental evidence from additional isolates is needed to validate the results according to their high genomic heterogeneity. In this study, we isolated different branches of strains and demonstrated that P. copri could improve the metabolic profile of hyperglycemic mice by modulating microbial activity. This finding supports the causal contribution of P. copri in host glucose metabolism.